Which is better, GYRE or RPRX?

On the Buffett-Fit framework, Royalty Pharma plc (RPRX) currently grades higher than GYRE — 66/100 (C grade) vs 44/100 (D). That said, "better" depends on which framework you trust — GYRE wins on Joel Greenblatt; RPRX wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy GYRE or RPRX?

This page is an educational comparison, not investment advice. Both GYRE and RPRX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is GYRE better than RPRX for value investing?

On the Buffett-style value-investing framework, RPRX currently grades higher — 66/100 vs 44/100, a 22-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between GYRE and RPRX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). GYRE currently scores 44/100 (D grade); RPRX scores 66/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, GYRE or RPRX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. GYRE and RPRX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, GYRE or RPRX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are GYRE and RPRX both Healthcare stocks?

Yes — both Gyre Therapeutics, Inc. (GYRE) and Royalty Pharma plc (RPRX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this GYRE vs RPRX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Gyre Therapeutics

Royalty Pharma

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

GYRE

Gyre Therapeutics

Market cap

$587.78M

Sector

Healthcare

RPRX

Royalty Pharma

Market cap

$23.44B

Sector

Healthcare

Overall winner

Royalty Pharma RPRX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	GYRE	RPRX	Winner
Warren Buffett	44D	66C	RPRX
Benjamin Graham	57D	84A	RPRX
Philip Fisher	60C	65C	RPRX
Peter Lynch	47D	60C	RPRX
Joel Greenblatt	44D	40D	GYRE
Charlie Munger	49D	68D	RPRX
Terry Smith	50C	58D	RPRX

Side-by-side metrics

Metric	GYRE	RPRX
Market cap	$587.78M	$23.44B
P/E (TTM)	-	27.6x
EV/EBIT	49.6x	19.9x
ROIC (TTM)	0.43%	8.43%
Gross margin	95.09%	99.95%
Net margin	-5.37%	33.91%
Revenue CAGR 5y	99.65%	0.96%
EPS CAGR 5y	-	11.83%
Debt / Equity	0.0x	1.3x
Dividend yield	0.0%	1.72%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

GYRE leads on

P/E (TTM)-vs 27.6x+130%
Debt / Equity0.0xvs 1.3x+99%
Revenue CAGR 5y99.65%vs 0.96%+99%

RPRX leads on

Net margin33.91%vs -5.37%+116%
Dividend yield1.72%vs 0.0%+100%
Market cap$23.44Bvs $587.78M+97%
ROIC (TTM)8.43%vs 0.43%+95%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Gyre Therapeutics

Royalty Pharma

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like GYRE

More like RPRX

Related on invest-like

Key terms in this analysis